VOICE study of Truvada gel (Gilead Sciences) unsuccessful in HIV prevention
Anti retroviral therapy was applied in the VOICE study which used a vaginal gel containing tenofovir (Viread as a pill) and tenofovir-emtricitabine (Truvada) from Gilead Sciences. None of the treatments was effective in the VOICE study, mostly because patients failed to use the product daily. 315 out of 5029 women in the study were infected by HIV (5.7%).
Investigators noted that the other HIV prevention studies (not Fem-PrEP) involving Truvada and Viread demonstrated an ability to reduce risk of infection when used consistently. In iPrEX study a PrEP dose of Truvada reduced HIV transmission by 44% among gay men.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins